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Interactions between cyclosporine A and adenosine in kidney trans-
plant recipients. Adenosine is involved in a large number of physiological
processes including immune response and vasomotor function. But its
precise involvement in renal physiology is poorly understood. We have
investigated the putative relationships between cyclosporine A (CsA) and
adenosine (ADO) metabolism in kidney transplant recipients (KTR). We
first compared ADO plasma levels in three groups of patients and in 10
controls: the first group (N 5 14) was composed of CsA-treated KTR; the
second group (N 5 5) was KTR not treated with CsA, and the third (N 5
6) was chronic kidney failure patients. We also measured ADO plasma
level in two KTR treated with FK506, a CsA analog. ADO plasma levels
in CsA-treated KTR were significantly higher (mean 0.76 mM 6 0.27) than
in the control group (mean 0.31 6 0.13; Mann-Whitney test, S 5 8.5; P 5
2.1 3 1024) and than in the chronic kidney failure group (0.37 6 0.16;
Mann-Whitney, S 5 5.5; P 5 1.6 3 1023). In CsA-treated KTR, CsA and
ADO plasma levels were significantly correlated (Spearman’s, r 5 0.8, P 5
1.9 3 1023). No significant differences in ADO plasma levels were found
between patients with chronic kidney failure and controls (P , 0.05).
ADO plasma levels in KTR not treated with CsA were in the same range
as those in controls. Finally, the ADO plasma level was increased in the
two FK506-treated patients. We also investigated the action of CsA on
ADO plasma degradation and uptake by erythrocytes in vitro. No inter-
action between adenosine deaminase and CsA was found because CsA, in
the presence of adenosine deaminase, did not modify the plasma half-life
of ADO. Conversely, in the presence of CsA (500 and 1000 ng/ml), the
uptake of ADO by erythrocytes was significantly decreased in adenosine
deaminase-free samples (analysis of variance, P 5 1.8.1023 and 1.2 3
1024, respectively). We conclude that ADO plasma levels are significantly
elevated and correlate with CsA blood level in CsA-treated KTR, and that
these high levels are due to CsA inhibition of ADO uptake by red cells.
Since ADO and metabolites have well known immunosuppressive and
vascular effects, ADO is likely to participate in the immune defect and in
the vasoconstriction induced by CsA.
In 1976 Borel et al [1] discovered cyclosporine A (CsA), a new
antilymphocytic agent, and in 1978 Calne et al [2] demonstrated
that CsA had marked beneficial effects in cases of organ trans-
plantation, which have been interpreted in terms of immunosup-
pressive effects [1–4]. However, the precise molecular mechanism
of CsA immunosuppression is unclear.
Adenosine (ADO) may be implicated in CsA immunosuppres-
sive effects, since ADO is a strong natural immunosuppressor [5,
6] whose metabolic abnormalities are associated with severe
combined immune deficiency [7].
Systemic hypertension and nephrotoxicity are two major side
effects that seem related to the vascular toxicity of CsA [8–10]. It
has been suggested that vasoactive humoral substances, including
angiotensin II [11, 12], prostaglandin [13–15], or endothelin
[16–18], mediate the renal vascular effects of CsA, but the role of
these substances is uncertain [19]. Increased renal ADO produc-
tion and release could be involved in CsA-induced changes in
renal hemodynamics for two reasons: (1) ADO receptor antago-
nists have beneficial effects in several experimental models of
acute renal failure, both nephrotoxic and hemodynamic [20, 21];
(2) ADO has strong protective effects against tissue ischemia
[reviewed in 22], and it is well established that CsA induces renal
vasoconstriction [8].
In light of these findings, the aim of the present study was
twofold. First we measured ADO plasma levels both in kidney
transplant recipients (KTR), receiving CsA therapy or not, and in
patients with chronic kidney failure and compared them with
those in control subjects; we also investigated ADO plasma level
in two KTR under FK506, a CsA analog [4, 23, 24]. Second, we
investigated the effects of CsA on the half-life of ADO in vitro to
determine if CsA can modulate the action of adenosine deami-
nase, and/or if CsA can modify ADO uptake by red blood cells
(RBC). These cells were chosen because their rapid up-take of
ADO is the prime cause of the very low concentration of ADO in
human blood [25]. Indeed, degradation to inosine by adenosine
deaminase and RBC uptake are the two principal means of
eliminating ADO in whole blood [25, 26].
METHODS
Patients were recruited in the Nephrology Department (Sainte
Marguerite Hospital, Marseille, France). Twenty-one KTR (14
CsA-treated, 2 FK506-treated, 5 non-CsA non-FK506-treated),
six patients with chronic renal failure and ten control subjects
participated in the study (Table 1). Among the fourteen CsA
treated patients, ten were under triple immunosuppressor therapy
including prednisone and azathioprine (Table 1) and four re-
ceived prednisone only. Ten of these fourteen were receiving
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antihypertensive drugs. The two FK506 treated patients were
under prednisone and did not receive antihypertensive drugs. The
five non-CsA-treated patients were under double immunosup-
pressive therapy (prednisone, azathioprine); two of them received
antihypertensive drugs. Patients with chronic renal failure were
not under immunosuppressor or antihypertensive drugs. Controls
were healthy subjects without any medication. For both patients
and controls, the ingestion of coffee or tea was suspended 72
hours before samples were taken. Patients treated with papaver-
ine, indomethacin or dipyridamole were excluded from the study.
No other treatments are known to interfere with the assay. All
patients gave their consent after being informed of the aims and
procedures of the study according to the Helsinki convention.
Adenosine assay
Adenosine (crystallized, 99% pure), adenosine deaminase (calf
intestine, specific activity 200 IU/mg) and dipyramidole (5 mg/ml)
were obtained from Boehringer Mannheim (France). Inosine
(99% pure), a,b-methylene-adenosine-59-diphosphate (AOPCP)
and deoxycoformycin (Pentostatin) were from Lederle. 9-Erythro
(2-hydroxy-3-nonyl) adenine (EHNA) was from Burroughs Wel-
come. Heparin (25 IU/ml) was from Choay Laboratory. Methanol
and other reagents were obtained from Merck (France). The
reversed phase chromatography column (Merck LIChrospher
C18, 250 3 4 mm) was obtained from Merck (France).
Equipment
Samples were analyzed by HPLC (Kratos HPLC 4000) with a 1
ml loop. Absorbance was measured at 254 nm, and eluted peak
areas were measured with a Shimatzu Chromatopac C-RCA
integrator.
Blood samples
Sample collection and treatment have been described previ-
ously [27–29]. Briefly, total venous blood (3 ml) was drawn
simultaneously with a stopping solution in Vacutainer tubes under
vacuum (one sample per patient). With this method, the blood
sample can be rapidly mixed with 10 ml of stopping solution,
which prevents ADO uptake by BRC [26, 30, 31]. We checked
that the mixed solution was correct by measuring hematocrits
(mean values 44% 6 3; mean values of the hematocrits with
stopping solution 17.6% 6 5). The stopping solution was com-
posed of 0.2 mM dipyridamole, 4.2 mM Na2EDTA, 5 mM EHNA,
79 mM AOPCP, heparin sulfate 1 IU/ml, and 0.9% NaCl. The
sample plus stopping solution was centrifuged at 2500 g for 10
minutes and the supernatant was deproteinized by adding 2 ml of
70% perchloric acid before a second centrifugation (2,500 g for 10
minutes). The supernatant was lyophilized and redissolved in 1 ml
of 50 mM sodium phosphate buffer (pH 4). The resulting solutions
were filtered by centrifugation in a Millipore Ultrafree-MC 0.45
mm filter before being chromatographed.
High pressure liquid chromatography
The high pressure liquid chromatography (HPLC) technique
has been described previously [27–29]. Briefly, plasma adenosine
was assayed by reversed phase HPLC on Merck C18 columns
(250 3 4 mm). The column was equilibrated with 50 mM sodium
phosphate buffer (pH 4). The sample was injected and was eluted
with a methanol gradient (0% to 46% methanol in 40 minutes) at
a flow rate of 1 ml/min. ADO was identified by elution time and
after incubation with adenosine deaminase, which increases the
inosine peak and decreases the ADO peak [27]. ADO was
quantified by comparing the peak areas given by known quantities
Table 1. Principal biological parameters of patients and controls
Kidney transplant
recipients
(CsA treated)
N 5 14
Kidney transplant
recipient
(non-CsA treated)
N 5 5
Kidney transplant
recipients
(FK506 treated)
N 5 2
Chronic kidney
failure patients
N 5 6
Controls
N 5 10
Age 46/14 39/14.8 51 51/12 36/11
Gender 4F/8M 4F/1M 1F 2F/4M 5F/5M
Duration of the graft
months
32/30 158/117 2
Serum creatinine mM 142/42 220/133 168 146/9 80/21
BUN mM 9.3/2.8 15.7/9.8 10.8 10.2/1.7 5.3/2.5
12 Hour whole blood
CsA or FK506
trough levels ng/ml
227/88 15
3 Hour whole blood
CsA peak levels
ng/ml
831/110
Plasma ADO level
mM
0.72/0.22 0.26/0.14 1.3 0.37/0.14 0.31/0.13
Mean blood pressure
mm Hg
100.3/10.08 106/13.2 96 94/8 80.7/10.09
Prednisone mg/day 12.1/2.6 18/2.7 15
Azathioprine mg/day 64.3/31 65/28
Data are means and standard deviations. Whole blood CsA was measured by radioimmunoassay with a monoclonal antibody, 3 hours (peak) and 12
hours (trough) after per os administration of the drug (Sandimmunt Sandoz Laboratories). ADO plasma levels were significantly higher in kidney
transplant recipients than in chronic renal failure group (Mann-Whitney test: S 5 5.5 P 5 1.6 3 1023) and than in controls (S 5 8.5, P 5 2.1 3 1024).
In non-CsA-treated kidney transplant recipients, ADO plasma levels were in the same range as those of controls. Finally, a high ADO plasma level was
found in the two FK506-treated patients. Abbreviations are: CsA, cyclosporine A; ADO, adenosine; BUN, blood urea nitrogen concentration.
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of adenosine. In these conditions, the sensitivity threshold was 10
pM injected in 1 ml.
In vitro experimental procedure
To determine the interaction between adenosine deaminase
and CsA, we mixed 1 ml aliquots of cell-free heparinized plasma
obtained by centrifugation (2500 g for 10 min) from whole blood
samples of six volunteers with 10 IU/ml of adenosine deaminase
plus CsA (Sandimmunt; Sandoz Laboratories, France) at 250 or
500 ng/ml. Samples were incubated for 5 minutes at 37°C with
continuous mixing by a Vortext system, after which 1 nmol (in 10
ml) of ADO was added. The degradation of adenosine was
stopped 5, 10, 15 and 30 seconds after ADO addition by using 3 ml
of cold stopping solution (see above). Samples were immediately
stored at 280°C before being chromatographed as described
above.
Adenosine uptake by red blood cells
Samples of 1 ml of RBC were washed three times with 5 ml of
0.9% NaCl. After the last wash, 5 IU/ml of heparin was added and
samples were mixed with 1 ml of a solution containing 0.9% NaCl,
2 mM CaCl2, 1 mg of deoxycoformycin, and 0.5 mg of indometh-
acin. Deoxycoformycin was added to prevent any action of
residual adenosine deaminase in the samples. Indomethacin was
added to prevent ADO release by cells during centrifugation [22].
The same procedure as described above for plasma samples was
then carried out. After centrifugation (1500 g for 10 min), the
supernatants were placed at 280°C before being chromato-
graphed.
Statistical analysis
The Mann-Whitney test was used to compare ADO plasma
levels between controls and patients. An analysis of variance was
used to compare ADO levels as a function of time in studies in
vitro. We used the Spearman correlation coefficient for correla-
tion studies.
RESULTS
Adenosine plasma levels
Adenosine plasma levels in CsA-treated KTR were significantly
higher (mean 0.76 mM 6 0.27) than in the healthy subject group
(mean 0.31 6 0.13; Mann-Whitney test S 5 8.5; P 5 2.1 3 1024)
and than those in the chronic kidney failure group (Mann-
Whitney, S 5 5.5; P 5 1.6 3 1023). On the basis of serum
creatinine, the chronic kidney failure group had the same renal
function as the CsA-treated KTR group (Table 1). In the CsA-
treated KTR group, CsA blood levels correlated both with ADO
plasma levels (Spearman’s R 5 0.8, P 5 1.9 3 1023, Fig. 1) and
with mean blood pressure (Spearman’s R 5 0.64, P 5 4.2 3 1022).
ADO plasma levels in non CsA, non-FK506-treated KTR (KTR
control group) were in the same range as those of the healthy
subjects (mean 0.26; SD 0.14). Finally, a high ADO plasma level
was also found in the two patients under FK506.
In vitro study
In cell-free plasma, CsA had no effect on ADO degradation by
adenosine deaminase, since the ADO half-life was not signifi-
cantly modified in the presence of 250 or 500 ng/ml of CsA
(analysis of variance P . 0.05 in both cases, Fig. 2).
In adenosine deaminase-free samples, ADO uptake by RBC in
the presence of 500 or 1000 ng/ml (but not 250 ng/ml) of CsA was
significantly lower than in controls (analysis of variance, P 5 1.8 3
1023, P 5 1.2 3 1024, and P . 0.05, respectively; Fig. 3). These
CsA sample levels are in the range of those observed in KTR
three hours after CsA per os administration (Table 1).
DISCUSSION
Our results demonstrate that the chronic administration of CsA
or analog to kidney transplant recipients is accompanied by high
plasma ADO levels. As all chromatographed samples were incu-
bated with adenosine deaminase, the enzyme that metabolizes
ADO into inosine, we can exclude that the high plasma ADO
Fig. 1. Correlation between adenosine (ADO) plasma levels and 12-hour
whole blood trough cyclosporine A (CsA) levels in 12 kidney transplant
recipients. Spearman’s R is 0.8; P 5 1.9 3 1023.
Fig. 2. Interaction between adenosine and cyclosporine in cell-free
plasma samples. Means and standard deviations of adenosine (ADO)
plasma level as a function of time. Sera of 6 volunteers were mixed with 10
IU/ml of adenosine deaminase and 250 or 500 ng/ml of cyclosporine
(Sandimmunt). ADO degradation was stopped by a cold stopping solu-
tion (Methods section) 5, 10, 15 and 30 seconds after 1 nM/ml ADO was
added in the samples. Symbols are: (n) 250 ng/ml; (F) controls; (E)
stopping solution; () 500 ng/ml; () 1000 ng/ml; *ANOVA P . 0.05.
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levels observed result from an interference between CsA adducts
and the ADO assay.
Because ADO has a very short half-life, elimination in urine is
not a classical metabolic pathway [22, 32]. This probably explains
why ADO plasma levels are not modified in the chronic kidney
failure group. It appears that the increase in ADO plasma levels
is induced by CsA administration for three reasons: (1) CsA
inhibits ADO uptake by RBC and increases its half-life in vitro; (2)
CsA blood levels are correlated with ADO plasma levels; (3) even
if there were too few non-CsA-treated KTR for statistical analysis,
their ADO plasma levels were in the same range as controls.
These findings show that the other immunosuppressive drugs
(prednisone and azathioprine) are not involved in ADO release.
Finally, CsA adducts are probably not implicated in the inhibition
of the ADO uptake by RBC since this inhibition began only a few
minutes after the in vitro incubation. However, even though CsA
adducts have few metabolic effects [1], we cannot speculate on
possible interactions between CsA adducts and ADO uptake by
RBC in vivo.
In fact, ADO is a powerful immunosuppressor via its transfor-
mation into deoxyadenosine, which is then preferentially con-
verted into the toxic compound deoxyadenosine triphosphate that
inhibits T cell functions [5–7]. Thus, adenosine deaminase defi-
ciency is accompanied by high ADO plasma levels and severe
combined immunodeficiency [6–7]. By binding to intracytoplas-
mic cyclophilin [33], CsA inhibits interleukin II and interferon g
mRNA production in T cells [34]. However, ADO plasma level
increase by CsA may be another mechanism that participates in
the immunosuppressive effects of CsA.
The increase in ADO plasma levels may also participate in
CsA-induced renal toxicity. Depending on its concentration, ADO
can decrease or increase renal blood flow because it interacts both
with high affinity A1 receptors inducing renal vasoconstriction
and with low affinity A2 receptors inducing vasodilation [35].
Contrary findings have been reported on the ability of ADO
receptors antagonists to reverse the CsA-induced renal vasocon-
striction. Some studies have shown that the ADO receptor
antagonist theophylline could not reverse acute CsA-induced
renal vasoconstriction [19, 36]. On the contrary, others in which
CsA was chronically administered have shown that pentoxyphillin,
a phosphodiesterase inhibitor that is also an adenosine antagonist
[37], decreases CsA nephrotoxicity [38–40]. The later result
suggests that the renal protective effects of pentoxyphilline are
mediated by the blockage of ADO action. In fact, the contradic-
tory results for ADO antagonists on CsA vascular effects may be
explained by the fact that ADO antagonists have opposite effects
in chronic and acute exposure to ADO [41].
It was reported that CsA can induce vasoconstriction directly by
acting on smooth muscle [42] or via the autonomic nervous system
[43]. This vasoconstriction may be responsible for oligemia-
induced ADO release, since ADO is released by cells in cases of
oligemia and/or tissue hypoxia, even minimally [22]. Finally, these
high ADO blood levels resulting both from CsA-induced inhibi-
tion of ADO uptake by RBC and probably from oligemia-induced
ADO release may play a role in CsA-induced renal vasoconstric-
tion.
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